Table 2. Inflammatory disease diagnosis, duration, and main anti-inflammatory medications at the time of inclusion for participants with systemic inflammation.
| Inflammatory disease | Disease duration (years or diagnosed at inclusion) | Main medication for inflammatory diagnosis at inclusion |
|---|---|---|
| Mixed crystal-induced arthropathy (CPPDa and gout) | 6 | Prednisone |
| Transient polyarthritis | Diagnosed at inclusion | No DMARDsb |
| Seropositive erosive rheumatoid arthritis | 20 | Prednisone |
| Inflammatory syndrome likely linked to multiple sclerosis | 1.5 | Ocrelizumab |
| VEXASc syndrome | 0.5 | Ruxolitinib, prednisone |
| Pigmented villonodular synovitis and metabolic syndrome | 0.5 | No DMARDs |
| Seronegative polyarthritis | 3 | NSAIDd; no DMARDs |
| Adult-onset Still disease | 0.3 | NSAID; no DMARDs |
| Peripheral spondyloarthritis | 9 | Certolizumab pegol |
| Giant cell arteritis | 1 | Abatacept, methotrexate, prednisone |
a
CPPD: calcium pyrophosphate crystal deposition disease.
b
DMARD: disease-modifying antirheumatic drug.
c
VEXAS: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic.
d
NSAID: nonsteroidal anti-inflammatory drug.